Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT: Optimal Treatment Target in Active Ulcerative Colitis
2024-514183-21-00Phase 4Completed
- Sponsor
- Alimentiv Inc.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 4, randomised trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Alimentiv Inc. Started Sep 2024; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-514183-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514183-21-00.